Logo

Arcis Biotechnology: Steve Howell

Jul 24, 2019

Arcis Biotechnology, a nucleic acid sample prep provider, has appointed Steve Howell as non-executive chairman of the board. Howell will replace Paul Foulger, who was serving as chairman of the board on an interim basis. Howell is a professor of commercial innovation at King's College, London, a position he has held since 2015. He founded Innova Partnerships in 2006, and has previously served as director of business development at Alere and research director at Unipath.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.